---
title: "Replimune Group, Inc. (REPL.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/REPL.US.md"
symbol: "REPL.US"
name: "Replimune Group, Inc."
industry: "Biotechnology"
datetime: "2026-04-16T09:01:58.158Z"
locales:
  - [en](https://longbridge.com/en/quote/REPL.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/REPL.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/REPL.US.md)
---

# Replimune Group, Inc. (REPL.US)

## Company Overview

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.replimune.com](https://www.replimune.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.60 | 154 | - | - | - |
| PB | 0.89 | 85 | 2.89 | 1.93 | 1.25 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-15T04:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Hold | 5 | 63% |
| Underweight | 1 | 13% |
| Sell | 2 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.28 |
| Highest Target | 19.00 |
| Lowest Target | 10.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/REPL.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/REPL.US/norm.md)
- [Related News](https://longbridge.com/en/quote/REPL.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/REPL.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**